Aegerion Pharmaceuticals, Inc. (AEGR) is a publicly traded company in the Unknown sector. Across all available filings, 33 corporate insiders have executed 351 transactions totaling $191.1M, demonstrating a bearish sentiment with -$85.7M in net insider flow. The most recent transaction on Nov 29, 2016 involved a transaction of 29,890 shares valued at $0.
No significant insider buying has been recorded for AEGR in the recent period.
No significant insider selling has been recorded for AEGR in the recent period.
Based on recent SEC filings, insider sentiment for AEGR is bearish with an Insider Alignment Score of 28/100 and a net flow of -$85.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Aegerion Pharmaceuticals, Inc. (AEGR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 33 insiders are actively trading AEGR stock, having executed 351 transactions in the past 90 days. The most active insider is Advisors Llc Perceptive (Executive), who has made 11 transactions totaling $88.2M.
Get notified when executives and directors at AEGR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 29, 2016 | J. Barer Sol | Executive | Disposition | 29,890 | $N/A | $0 | |
| Nov 29, 2016 | Scheer David | Executive | Disposition | 521,350 | $N/A | $0 | |
| Nov 29, 2016 | Scheer David | Executive | Disposition | 10,000 | $N/A | $0 | |
| Nov 29, 2016 | M. Jr Md D. Phil Gotto Antonio | Executive | Disposition | 13,916 | $N/A | $0 | |
| Nov 29, 2016 | D. Smith Sandford | Executive | Disposition | 2,890 | $N/A | $0 | |
| Nov 29, 2016 | Thomas Paul | Executive | Disposition | 36,978 | $N/A | $0 | |
| Nov 29, 2016 | Vanlent Anne | Executive | Disposition | 4,000 | $N/A | $0 | |
| Nov 29, 2016 | Harshbarger Benjamin | Executive | Disposition | 1,704 | $N/A | $0 | |
| Nov 29, 2016 | Master Fund Ltd Broadfin Healthcare | Executive | Disposition | 4,361,291 | $N/A | $0 | |
| Sep 17, 2016 | Harshbarger Benjamin | Executive | Option Exercise | 1,642 | $N/A | $0 | |
| Sep 17, 2016 | Harshbarger Benjamin | Executive | Payment | 532 | $1.78 | $947 | |
| Sep 13, 2016 | Master Fund Ltd Broadfin Healthcare | Executive | Purchase | 75,000 | $1.75 | $131.3K | |
| Sep 12, 2016 | Llc Broadfin Capital, | Executive | Purchase | 76,000 | $1.70 | $129.2K | |
| Sep 12, 2016 | Llc Broadfin Capital, | Executive | Purchase | 100,000 | $1.70 | $170.0K | |
| Sep 9, 2016 | Llc Broadfin Capital, | Executive | Purchase | 100,000 | $1.60 | $160.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 164 | $138.4M | 54.0% |
Purchase(P) | 73 | $52.7M | 20.6% |
Conversion(C) | 42 | $49.9M | 19.5% |
Exercise (Options)(X) | 5 | $13.1M | 5.1% |
Exercise(M) | 43 | $2.1M | 0.8% |
Payment(F) | 4 | $8.4K | 0.0% |
Disposition(D) | 9 | $0 | 0.0% |
Other(J) | 4 | $0 | 0.0% |
Gift(G) | 5 | $0 | 0.0% |
Award(A) | 2 | $0 | 0.0% |
Insider selling pressure at Aegerion Pharmaceuticals, Inc. has increased, with 33 insiders executing 351 transactions across all time. Total sales of $138.4M significantly outpace purchases of $52.7M, resulting in a net outflow of $85.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.